Valuation: Alvotech

Market Cap 1.7B 1.52B 1.4B 1.27B 2.38B 161B 2.41B 16.84B 6.69B 84.41B 6.36B 6.23B 268B P/E 2026 *
114x
P/E 2027 * 15.9x
Enterprise Value 2.77B 2.49B 2.3B 2.08B 3.89B 263B 3.94B 27.53B 10.93B 138B 10.4B 10.18B 437B EV / Sales 2026 *
4.25x
EV / Sales 2027 * 3.5x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+2.11%
1 week-6.85%
Current month-17.79%
1 month-19.05%
3 months+49.45%
6 months+40.00%
Current year+2.50%
1 week 45.25
Extreme 45.25
51.2
1 month 45.25
Extreme 45.25
64.9
Current year 27.5
Extreme 27.5
64.9
1 year 27.5
Extreme 27.5
79.44
3 years 27.5
Extreme 27.5
157
5 years 27.5
Extreme 27.5
157
10 years 27.5
Extreme 27.5
157
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 57 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.92%-6.85% - - 1.7B
+0.65%-3.56%+33.53%+60.50% 63.48B
+2.84%+2.42%+13.08%+84.18% 54.55B
-0.93%+1.25%+10.73%+102.70% 53.59B
+3.33%+0.86%+27.91%+57.49% 44.75B
+2.34%-3.49%+17.72%+99.87% 41.62B
+0.78%-4.23%+219.86%+913.95% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+24.47%+38.17%+93.84%+81.82% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average +3.89%-0.67%+50.41%+159.65% 42.27B
Weighted average by Cap. +3.03%-0.48%+46.39%+159.25%

Financials

2026 *2027 *
Net sales 653M 586M 541M 490M 917M 61.99B 928M 6.48B 2.58B 32.49B 2.45B 2.4B 103B 786M 705M 651M 591M 1.1B 74.65B 1.12B 7.81B 3.1B 39.13B 2.95B 2.89B 124B
Net income 2.25M 2.02M 1.86M 1.69M 3.15M 213M 3.19M 22.32M 8.86M 112M 8.43M 8.25M 355M 80.1M 71.89M 66.38M 60.19M 113M 7.61B 114M 796M 316M 3.99B 301M 294M 12.65B
Net Debt 1.08B 965M 891M 808M 1.51B 102B 1.53B 10.69B 4.24B 53.55B 4.04B 3.95B 170B 1.06B 948M 875M 794M 1.48B 100B 1.5B 10.49B 4.17B 52.57B 3.96B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-10-28 SEK 49.10 +6.16% 11,129
26-10-27 SEK 46.25 +1.54% 29,137
26-10-26 SEK 45.55 -1.09% 26,588
26-10-23 SEK 46.05 -6.40% 39,458
26-10-22 SEK 49.20 -3.72% 23,101
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.750USD
Average target price
7.200USD
Spread / Average Target
+51.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech